We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
- Authors
Bolandi, Nadia; Derakhshani, Afshin; Hemmat, Nima; Baghbanzadeh, Amir; Asadzadeh, Zahra; Afrashteh Nour, Mina; Brunetti, Oronzo; Bernardini, Renato; Silvestris, Nicola; Baradaran, Behzad
- Abstract
Gastric cancer (GC), with a heterogeneous nature, is the third leading cause of death worldwide. Over the past few decades, stable reductions in the incidence of GC have been observed. However, due to the poor response to common treatments and late diagnosis, this cancer is still considered one of the lethal cancers. Emerging methods such as immunotherapy with immune checkpoint inhibitors (ICIs) have transformed the landscape of treatment for GC patients. There are presently eleven known members of the B7 family as immune checkpoint molecules: B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), B7-DC (PDCD1LG2, PD-L2, CD273), B7-H2 (B7RP1, ICOS-L, CD275), B7-H3 (CD276), B7-H4 (B7x, B7S1, Vtcn1), B7-H5 (VISTA, Gi24, DD1α, Dies1 SISP1), B7-H6 (NCR3LG1), B7-H7 (HHLA2), and Ig-like domain-containing receptor 2 (ILDR2). Interaction of the B7 family of immune-regulatory ligands with the corresponding receptors resulted in the induction and inhibition of T cell responses by sending co-stimulatory and co-inhibitory signals, respectively. Manipulation of the signals provided by the B7 family has significant potential in the management of GC.
- Subjects
FAMILY roles; IMMUNE checkpoint proteins; STOMACH cancer; CANCER treatment; IMMUNE checkpoint inhibitors
- Publication
International Journal of Molecular Sciences, 2021, Vol 22, Issue 19, p10719
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms221910719